Prediction of ARrhythmic Events With Positron Emission Tomography II

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    State University of New York at Buffalo
Updated on 23 January 2021
coronary artery disease
artery disease
medical therapy
ejection fraction
enzyme inhibitors
myocardial infarction
beta blockers
b-type natriuretic peptide
ace inhibitor
natriuretic peptide
brain natriuretic peptide
cardiac death
primary prevention
beta-adrenergic blocking agents
sympathetic denervation
sudden cardiac death
angiotensin converting enzyme


Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrating a reduction in left ventricular ejection fraction less than 35%. The purpose of this observational cohort study is to prospectively test whether this can be enhanced by quantifying the amount of sympathetic denervation, left ventricular end-diastolic volume or brain natriuretic peptide levels.


Using current guidelines based primarily on ejection fraction (EF), only one-quarter of patients receiving an implantable cardiac defibrillator (ICD) for the primary prevention of sudden cardiac arrest (SCA) require appropriate ICD therapy within 5 years. The NIH-sponsored PAREPET study (Prediction of ARrhythmic Events with Positron Emission Tomography,, NCT01400334) identified four independent risk factors that predict SCA or ICD equivalent in patients with ischemic cardiomyopathy. Using retrospectively defined cut-points, the absence of these risk factors identified 38% of the cohort with a very low risk of SCA (<1% per year). This rate is actually lower than the 1.5-2% annual rate of SCA among patients with coronary artery disease and mild left ventricular (LV) dysfunction, who are not considered candidates for a primary prevention ICD. This proposal will prospectively determine whether these risk factors can form the basis of a clinically applicable approach to identify a subgroup of patients who are candidates for an ICD, but are at low enough risk of SCA to have an ICD safely withheld. Our long-term goal is to develop better approaches to identify patients with coronary artery disease who are most likely to benefit from prevention of SCA with placement of an implantable defibrillator.

Condition Sudden Cardiac Death, Heart failure, Heart disease, Ischemic Cardiomyopathy, Congestive Heart Failure, Cardiac Disease, sudden cardiac arrest, congestive heart disease
Treatment PET scan quantifying sympathetic denervation using [18F]-LMI1195
Clinical Study IdentifierNCT03493516
SponsorState University of New York at Buffalo
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Heart failure or Sudden Cardiac Death or Congestive Heart Failure or Cardiac Disease or Heart disease or Ischemic Cardiomyopathy?
Do you have any of these conditions: Sudden Cardiac Death or sudden cardiac arrest or Congestive Heart Failure or Heart failure or congestive heart disease or Ischemic Cardiomyopathy or H...?
Coronary artery disease (by cardiac catheterization or definite myocardial infarction)
ICD implantation for the primary prevention of SCA
Medical therapy including beta-blockers and angiotensin inhibition therapy [angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARA)]

Exclusion Criteria

Plans for coronary revascularization (due to the independent impact on SCA)
Contraindication for PET (i.e. claustrophobia, pregnancy, physical limitation)
Tricyclic antidepressant use (inhibits norepinephrine and LMI1195 uptake)
Comorbidities limiting life expectancy <2yr
Age <18 years or inability to provide informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note